These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 27348250)

  • 1. Safety and immunogenicity of 3 seasonal trivalent influenza vaccines in the Chinese military.
    Gao D; Yang H; Deng B; Yin G; Song W; Zhang H; Li Y
    Hum Vaccin Immunother; 2016 Oct; 12(10):2634-2639. PubMed ID: 27348250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and safety of three 2010-2011 seasonal trivalent influenza vaccines in Chinese toddlers, children and older adults: a double-blind and randomized trial.
    Luo FJ; Yang LQ; Ai X; Bai YH; Wu J; Li SM; Zhang Z; Lu M; Li L; Wang ZY; Shi NM
    Hum Vaccin Immunother; 2013 Aug; 9(8):1725-34. PubMed ID: 23896581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity, safety and reactogenicity of a mammalian cell-culture-derived influenza vaccine in healthy children and adolescents three to seventeen years of age.
    Vesikari T; Block SL; Guerra F; Lattanzi M; Holmes S; Izu A; Gaitatzis N; Hilbert AK; Groth N
    Pediatr Infect Dis J; 2012 May; 31(5):494-500. PubMed ID: 22301476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, immunogenicity and cross-reactivity of a Northern hemisphere 2013-2014 seasonal trivalent inactivated split influenza virus vaccine, Anflu®.
    Shen Y; Hu Y; Meng F; Du W; Li W; Song Y; Ji X; Huo L; Fu Z; Yin W
    Hum Vaccin Immunother; 2016 May; 12(5):1229-34. PubMed ID: 26934750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and safety of an inactivated 2012/2013 trivalent influenza vaccine produced in mammalian cell culture (Optaflu®): an open label, uncontrolled study.
    Vinnemeier CD; Fischer-Herr J; Meyer S; Liebig K; Theeß W; Burchard GD; Cramer JP
    Hum Vaccin Immunother; 2014; 10(2):441-8. PubMed ID: 24240428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 2013/2014 northern hemisphere season surface antigen inactivated trivalent influenza vaccine--Assessing the immunogenicity and safety in an open label, uncontrolled study.
    Roggelin L; Vinnemeier CD; Meyer S; Witte K; Marx L; Theeß W; Burchard GD; Rolling T; Cramer JP
    Hum Vaccin Immunother; 2015; 11(10):2370-5. PubMed ID: 26114800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunological persistence of a seasonal influenza vaccine in people more than 3 years old.
    Bai Y; Shi N; Lu Q; Yang L; Wang Z; Li L; Han H; Zheng D; Luo F; Zhang Z; Ai X
    Hum Vaccin Immunother; 2015; 11(7):1648-53. PubMed ID: 26083828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 years.
    Domachowske JB; Pankow-Culot H; Bautista M; Feng Y; Claeys C; Peeters M; Innis BL; Jain V
    J Infect Dis; 2013 Jun; 207(12):1878-87. PubMed ID: 23470848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, double-blind, non-inferiority trial comparing the immunogenicity and safety of two seasonal inactivated influenza vaccines in adults.
    Vanni T; da Graça Salomão M; Viscondi JYK; Braga PE; da Silva A; de Oliveira Piorelli R; do Prado Santos J; Gattás VL; Lucchesi MBB; de Oliveira MMM; Koike ME; Campos LMA; Coelho EB; Weckx LY; Lara AN; Paiva TM; Timenetsky MDCST; Precioso AR
    Vaccine; 2023 May; 41(22):3454-3460. PubMed ID: 37121800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of a seasonal trivalent inactivated split influenza vaccine: a phase I randomized clinical trial in healthy Serbian adults.
    Stevanovic G; Lavadinovic L; Filipovic Vignjevic S; Holt R; Ilic K; Berlanda Scorza F; Sparrow E; Stoiljkovic V; Torelli G; Madenwald T; Socquet M; Barac A; Ilieva-Borisova Y; Pelemis M; Flores J
    Hum Vaccin Immunother; 2018 Mar; 14(3):579-586. PubMed ID: 29239682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase IV: randomized controlled trial to evaluate lot consistency of trivalent split influenza vaccines in healthy adults.
    Song JY; Cheong HJ; Lee J; Wie SH; Park KH; Kee SY; Jeong HW; Kim YS; Noh JY; Choi WS; Park DW; Sohn JW; Kim WJ
    Hum Vaccin Immunother; 2014; 10(10):2958-64. PubMed ID: 25483462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intradermally-administered influenza virus vaccine is safe and immunogenic in healthy adults 18-64 years of age.
    Gorse GJ; Falsey AR; Fling JA; Poling TL; Strout CB; Tsang PH
    Vaccine; 2013 May; 31(19):2358-65. PubMed ID: 23499604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A reduced-dose seasonal trivalent influenza vaccine is safe and immunogenic in adult and elderly patients in a randomized controlled trial.
    Vajo Z; Tamas F; Jankovics I
    Clin Vaccine Immunol; 2012 Mar; 19(3):313-8. PubMed ID: 22219315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine: a randomized, double-blind, controlled phase III clinical trial in children aged 6-35 months in China.
    Hu Y; Shao M; Hu Y; Liang Q; Jia N; Chu K; Xu L; Li J; Li C; Zhu F
    Hum Vaccin Immunother; 2020 Jul; 16(7):1691-1698. PubMed ID: 32347785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A dose-ranging study in older adults to compare the safety and immunogenicity profiles of MF59®-adjuvanted and non-adjuvanted seasonal influenza vaccines following intradermal and intramuscular administration.
    Della Cioppa G; Nicolay U; Lindert K; Leroux-Roels G; Clement F; Castellino F; Galli C; Groth N; Levin Y; Del Giudice G
    Hum Vaccin Immunother; 2014; 10(6):1701-10. PubMed ID: 24732325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review of 10 years of clinical experience with Chinese domestic trivalent influenza vaccine Anflu®.
    Liu Y; Wu JY; Wang X; Chen JT; Xia M; Hu W; Zou Y; Yin WD
    Hum Vaccin Immunother; 2014; 10(1):73-82. PubMed ID: 24104060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of the novel seasonal preservative- and adjuvant-free influenza vaccine: Blind, randomized, and placebo-controlled trial.
    Sarsenbayeva G; Volgin Y; Kassenov M; Issagulov T; Bogdanov N; Sansyzbay A; Abitay R; Nurpeisova A; Sagymbay A; Koshemetov Z; Stukova M; Buzitskaya Z; Кulmagambetov I; Karabayeva D; Davlyatshin T; Khairullin B
    J Med Virol; 2018 Jan; 90(1):41-49. PubMed ID: 28842994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of an investigational tetravalent influenza vaccine formulation combining MF59®: adjuvanted, pre-pandemic, A/H5N1 vaccine and trivalent seasonal influenza vaccine in healthy adults.
    Herbinger KH; von Sonnenburg F; Nothdurft HD; Perona P; Borkowski A; Fragapane E; Nicolay U; Clemens R
    Hum Vaccin Immunother; 2014; 10(1):92-9. PubMed ID: 24047817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity, safety and consistency of new trivalent inactivated influenza vaccine.
    Talbot HK; Keitel W; Cate TR; Treanor J; Campbell J; Brady RC; Graham I; Dekker CL; Ho D; Winokur P; Walter E; Bennet J; Formica N; Hartel G; Skeljo M; Edwards KM
    Vaccine; 2008 Jul; 26(32):4057-61. PubMed ID: 18602726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and safety of an egg-based inactivated quadrivalent influenza vaccine (GC3110A) versus two inactivated trivalent influenza vaccines with alternate B strains: A phase Ⅲ randomized clinical trial in adults.
    Song JY; Lee J; Woo HJ; Wie SH; Lee JS; Kim SW; Kim TH; Jung SI; Noh JY; Choi WS; Cheong HJ; Kim WJ
    Hum Vaccin Immunother; 2019; 15(3):710-716. PubMed ID: 30396317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.